Physician profile
Robert F Stringer
NPI 1861497117
$5,074.60
in general payments reported to CMS, 2019-2025
5 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $2,399 · 2021: $27.52 · 2022: $1,627 · 2023: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $725 · Food and Beverage: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $724.50 |
| Food and Beverage | $296.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $4,117.78 | 2020-2023 | |
| Titan Surgical Group, LLC | $909.95 | 2021-2023 | |
| Bioventus LLC | $16.67 | 2023 | Durolane |
| Kowa Pharmaceuticals America, INC. | $15.20 | 2023 | Seglentis |
| Pacira Pharmaceuticals Incorporated | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stringer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.